Serge PAMPFER

Lovaltech is a company created in 2022 to exploit the untapped potential of the mucosal immune system and to develop nasal vaccines against respiratory pathogens like covid and flu as first indications. The key advantages of these vaccines are their ability to block transmission, the protection against multivariants, the formulation without adjuvant and the stability at positive temperature. The first vaccine, LVT-001, is planned to start clinical phases I/II by the end of 2024. The company has concluded a € 6,8 M€ seed round in early 2024 and is preparing a Series A round to expand the pipeline towards other infectious and non-infectious diseases. The business model of Lovaltech calls for the out-licensing of their products to biopharma partners after completion of clinical phase II.